Publications

1. Tremblay D, Csizmar C, DiNardo CD, Ball S, Rippel N, Hammond D, Kadia TM, Ravandi F, Chien K, Van Hyfte G, Mazumdar M, Saliba A, Mangaonkar A, Lasho T, Al-Kali A, Kremyanskaya M, Feld J, Silverman LR, Komrokji R, Mascarenhas J, Padron E, Garcia-Manero G, Sallman DA, Patnaik MM, Montalban-Bravo G. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study. Leukemia. 2024 Nov 12 [Epub ahead of print]
   View PubMed
2. Jabban Y, Yacout M, Baranwal A, He R, Viswanatha D, Greipp P, Jevremovic D, Bessonen K, Foran J, Palmer J, Saliba AN, Hefazi-Torghabeh M, Begna K, Hogan WJ, Mangaonkar A, Patnaik M, Shah M, Alkhateeb H, Al-Kali A. Clinical outcomes of patients diagnosed with SETBP1 mutated myeloid neoplasms. Leuk Lymphoma. 2024 Nov 6; 1-10 Epub 2024 Nov 06
   View PubMed
3. Badar T, Nanaa A, Atallah E, Shallis RM, Craver EC, Li Z, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy GSG, Zeidan AM, Kota V, Patnaik MM, Litzow MR. Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases. Haematologica. 2024 Nov 1; 109 (11):3533-3542 Epub 2024 Nov 01
   View PubMed
4. Csizmar CM, Saliba AN, Greipp PT, Alkhateeb H, Begna KH, Foran JM, Gangat N, Hogan WJ, Hook CC, Litzow MR, Mangaonkar AA, Palmer JM, Pardanani A, Shah MV, Tefferi A, Torghabeh MH, Wolanskyj-Spinner AP, Patnaik MM, Kaufmann SH, Al-Kali A. FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): the Mayo Clinic experience. Haematologica. 2024 Nov 1; 109 (11):3785-3789 Epub 2024 Nov 01
   View PubMed
5. Katamesh B, Nanaa A, He R, Viswanatha D, Greipp PT, Bessonen K, Nguyen P, Jevremovic D, Yi CA, Foran J, Begna K, Gangat N, Mangaonkar A, Saliba AN, Patnaik MM, Hogan WJ, Litzow M, Tefferi A, Shah MV, Alkhateeb HB, Al-Kali A. Clonal heterogeneity in STAG2m myeloid neoplasms: the Mayo Clinic experience. Ann Hematol 2024 Oct; 103 (10):4333-4336 Epub 2024 Aug 28
   View PubMed
6. Yacout M, Katamesh B, Jabban Y, He R, Viswanatha D, Jevremovic D, Greipp P, Bessonen K, Palmer J, Foran J, Saliba A, Hefazi-Torghabeh M, Begna K, Hogan W, Patnaik M, Shah M, Alkhateeb H, Al-Kali A. Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms. Leukemia. 2024 Sep 23 Epub 2024 Sept 23
   View PubMed
7. Murthy GSG, Saliba AN, Szabo A, Harrington A, Abedin S, Carlson K, Michaelis L, Runaas L, Baim A, Hinman A, Maldonado-Schmidt S, Venkatachalam A, Flatten KS, Peterson KL, Schneider PA, Litzow M, Kaufmann SH, Atallah E. A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia. Haematologica. 2024 Sep 1; 109 (9):2864-2872 Epub 2024 Sept 01
   View PubMed
8. Steinauer N, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, Saliba AN, Torghabeh M, Litzow MR, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Yi CA, Tefferi A, Gangat N. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent. Haematologica 2024 Aug 1; 109 (8):2706-2710 Epub 2024 Aug 01
   View PubMed
9. Kjellesvig S, Zaworski E, Saliba AN. Acute Myelomonocytic Leukemia Presenting as Fournier's Gangrene. WMJ. 2024 May; 123 (2):131-134
   View PubMed
10. Jia J, Ji W, Saliba AN, Csizmar CM, Ye K, Hu L, Peterson KL, Schneider PA, Meng XW, Venkatachalam A, Patnaik MM, Webster JA, Smith BD, Ghiaur G, Wu X, Zhong J, Pandey A, Flatten KS, Deng Q, Wang H, Kaufmann SH, Dai H. AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death. Cell Death Differ. 2024 Apr; 31 (4):405-416 Epub 2024 Mar 27
    View PubMed
11. Johnson IM, Karrar O, Rana M, Iftikhar M, Chen S, McCullough K, Saliba AN, Al-Kali A, Alkhateeb H, Begna K, Litzow M, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Hermann J, Tefferi A, Gangat N. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. Br J Haematol. 2024 Apr; 204 (4):1232-1237 Epub 2024 Feb 04
    View PubMed
12. Lewis AR, Choong GM, Cathcart-Rake E, Florez N, Durani U, Yadav S, Fuentes H, Sorensen K, Childs DS, Saliba A, Paludo J, Hobday TJ. Preparing Hematology/Oncology Fellows for Success: Implementing an Annual Career Development and Research Retreat. J Cancer Educ. 2024 Feb; 39 (1):58-64 Epub 2023 Oct 17
    View PubMed
13. Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024 Feb; 99 (2):193-202 Epub 2023 Dec 10
    View PubMed
14. Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Saliba A, Torghabeh MH, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Badar T, Foran J, Palmer J, Sproat L, Yi CA, Tefferi A. Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia. Haematologica 2024 Jan 1; 109 (1):187-292 Epub 2024 Jan 01
    View PubMed
15. Saliba AN, Musallam KM, Taher AT. How I treat non-transfusion-dependent beta-thalassemia. Blood. 2023 Sep 14; 142 (11):949-960
    View PubMed
16. Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2023 Jun 13; 7 (11):2360-2363
    View PubMed
17. Badar T, Litzow MR, Shallis RM, Patel A, Saliba AN, Burkart M, Bewersdorf JP, Stahl M, De Camargo Correia GS, Guru Murthy GS, Abaza Y, Duvall A, Bradshaw D, Kota V, Dinner S, Goldberg AD, Palmisiano N, Al Kali A, Atallah E. Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer. 2023 Mar 15; 129(6):934-945. Epub 2022 Dec 21.
    View PubMed
18. El Hasbani G, Saliba AN, Uthman I, Taher AT. Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis. Blood Rev. 2023 Mar; 58:101015 Epub 2022 Sept 16
    View PubMed
19. Bizri M, Ibrahim N, El Hayek S, Saliba A, Ehlers SL, Ostroff JS, Maalouf F, Taher A. Challenges in implementing psycho-oncology services in Arab low- and middle-income countries: Lessons learned from Lebanon. Psychooncology. 2023 Jan; 32 (1):174-178 Epub 2022 Aug 17
    View PubMed
20. King JM, Akel R, Saliba AN, Wei C, Anouti B, Manchanda N, Sinex NC, Grethlein SJ, Goldman M. Innovation in Resident Core Oncology Education: Switching from an Inpatient Ward Rotation to a Hybrid Model of Inpatient Consultations and Outpatient Clinics. J Cancer Educ. 2022 Dec; 37 (6):1768-1772 Epub 2021 May 14
    View PubMed
21. Saliba AN, Gangat N. Accelerated and blast phase myeloproliferative neoplasms. Best Pract Res Clin Haematol. 2022 Jun; 35(2):101379. Epub 2022 Aug 30.
    View PubMed
22. Peseski AM, Saliba AN, Althouse SK, Sayar H. Does Race Play a Role in Complications and Outcomes of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms? Hematol Oncol Stem Cell Ther. 2022 Jun 1; 15 (2):30-38 Epub 2022 June 01
    View PubMed
23. Hwang SR, Saliba AN, Wolanskyj-Spinner AP. Immunotherapy-associated Autoimmune Hemolytic Anemia. Hematol Oncol Clin North Am. 2022 Apr; 36(2):365-380.
    View PubMed
24. Hickman AD, Saliba AN, Nowakowski GS. 67-Year-Old Woman With Diarrhea and Weight Loss. Mayo Clin Proc. 2022 Feb; 97(2):364-369.
    View PubMed
25. Csizmar CM, Saliba AN, Swisher EM, Kaufmann SH. PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. Cancers (Basel). 2021 Dec 20; 13(24).
    View PubMed
26. Ezzeddine FM, Saliba AN, Jain V, Villarraga HR, Herrmann J, Asirvatham SJ, Cha YM. Outcomes of cardiac resynchronization therapy in patients with chemotherapy-induced cardiomyopathy. Pacing Clin Electrophysiol. 2021 Apr; 44 (4):625-632 Epub 2021 Mar 15
    View PubMed
27. Bezerra ED, Lasho TL, Finke CM, Saliba AN, Elliott MA, Pardanani AD, Gangat N, Mangaonkar AA, Ketterling RP, Tefferi A, Solary E, Patnaik MM. CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. Blood Cancer J 2021 Mar 11; 11 (3):54
    View PubMed
28. Patel SR, Saliba AN, Steel S, Liewluck T, Mahipal A. Metastatic Colon Cancer Presenting With Immune-mediated Necrotizing Myopathy. Clin Colorectal Cancer. 2021 Mar; 20 (1):e71-e73 Epub 2020 Aug 29
    View PubMed
29. Xie Z, Nanaa A, Saliba AN, He R, Viswanatha D, Nguyen P, Jevremovic D, Greipp P, Salama ME, Gangat N, Alkhateeb HB, Tefferi A, Litzow M, Patnaik M, Shah M, Al-Kali A. Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer J 2021 Mar 1; 11 (3):43 Epub 2021 Mar 01
    View PubMed
30. Grach SL, Saliba AN, Costello BA. 40-Year-Old Man With Left Leg Swelling and Abdominal Pain. Mayo Clin Proc. 2021 Mar; 96 (3):782-787
    View PubMed
31. Saliba AN, John AJ, Kaufmann SH. Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia. Cancer Drug Resist. 2021; 4(1):125-142. Epub 2021 Mar 19.
    View PubMed
32. Saliba AN, Atoui A, Labban M, Hamade H, Bou-Fakhredin R, Mufarrij A, Taher AT. Thalassemia in the emergency department: special considerations for a rare disease. Ann Hematol. 2020 Sep; 99 (9):1967-1977 Epub 2020 July 03
    View PubMed
33. Saliba AN, Ferrer A, Gangat N, Pruthi RK, Tefferi A, Higgins A, Bezerra ED, Buglioni A, Salama ME, Klee EW, Pinto E Vairo F, Mangaonkar A, Majerus J, Chen D, Patnaik MM. Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients. Br J Haematol 2020 Sep; 190 (5):e316-e320 Epub 2020 June 22
    View PubMed
34. Sleiman J, Tarhini A, Bou-Fakhredin R, Saliba AN, Cappellini MD, Taher AT. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. Int J Mol Sci. 2018 Jan 8; 19 (1) Epub 2018 Jan 08
    View PubMed
35. Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program. 2017 Dec 8; 2017 (1):265-271
    View PubMed
36. Taher AT, Saliba AN, Kuo KH, Giardina PJ, Cohen AR, Neufeld EJ, Aydinok Y, Kwiatkowski JL, Jeglinski BI, Pietropaolo K, Berk G, Viprakasit V. Safety and pharmacokinetics of the oral iron chelator SP-420 in beta-thalassemia. Am J Hematol. 2017 Dec; 92 (12):1356-1361 Epub 2017 Oct 31
    View PubMed
37. Saliba AN, Taher AT. Morbidities in non-transfusion-dependent thalassemia. Ann N Y Acad Sci. 2016 Mar; 1368 (1):82-94
    View PubMed
38. Tamim H, Habbal M, Saliba A, Musallam K, Al-Taki M, Hoballah J, Jamali S, Taher A. Preoperative INR and postoperative major bleeding and mortality: A retrospective cohort study. J Thromb Thrombolysis. 2016 Feb; 41 (2):301-11
    View PubMed
39. Saliba AN, El Rassi F, Taher AT. Clinical monitoring and management of complications related to chelation therapy in patients with beta-thalassemia. Expert Rev Hematol. 2016; 9 (2):151-68 Epub 2015 Dec 19
    View PubMed
40. Saliba AN, Taher AT, Tamim H, Harb AR, Mailhac A, Radwan A, Jamali FR. Impact of Resident Involvement in Surgery (IRIS-NSQIP): Looking at the Bigger Picture Based on the American College of Surgeons-NSQIP Database. J Am Coll Surg. 2016 Jan; 222 (1):30-40 Epub 2015 Oct 27
    View PubMed
41. Amid A, Saliba AN, Taher AT, Klaassen RJ. Thalassaemia in children: from quality of care to quality of life. Arch Dis Child. 2015 Nov; 100 (11):1051-7 Epub 2015 Aug 19
    View PubMed
42. Saliba A, Taher A. Iron overload in transfusion-dependent thalassemia. Hematology. 2015 Jun; 20 (5):311-2
    View PubMed
43. Saliba AN, Harb AR, Taher AT. Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med. 2015; 6:197-209 Epub 2015 June 17
    View PubMed